Compare · INBS vs MDLN
INBS vs MDLN
Side-by-side comparison of Intelligent Bio Solutions Inc. (INBS) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INBS and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $50.91B, about 12161.7x INBS ($4.2M).
- Over the past year, INBS is down 89.0% and MDLN is down 4.8% - MDLN leads by 84.2 points.
- MDLN has been more active in the news (5 items in the past 4 weeks vs 4 for INBS).
- MDLN has more recent analyst coverage (25 ratings vs 0 for INBS).
PerformanceINBS-70.40%MDLN-4.83%
2025-12-17+0.00%2026-07-24
- Company
- Intelligent Bio Solutions Inc.
- Medline Inc.
- Price
- $1.77-1.12%
- $38.78+3.02%
- Market cap
- $4.2M
- $50.91B
- 1M return
- -19.18%
- +7.57%
- 1Y return
- -89.01%
- -4.83%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2025
- News (4w)
- 4
- 5
- Recent ratings
- 0
- 25
Latest INBS
- Intelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Intelligent Bio Solutions Achieves Key Milestone Ahead of Planned FDA 510(k) Submission, Advancing Toward Planned U.S. Market Entry
- Intelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market
- Intelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry
- Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18
- Intelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission
- SEC Form SCHEDULE 13G filed by Intelligent Bio Solutions Inc.
Latest MDLN
- Medline strengthens California distribution network with new 1 million-square-foot facility in Perris
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)